Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2015)
Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysisJ Am Coll Cardiol, 65
(2011)
Apixaban versus warfarin in patients with atrial fibrillationN Engl J Med, 365
(2015)
Embolization of left atrial appendage closure devices: a systematic review of cases reported with the watchman device and the amplatzer cardiac plugCatheter Cardiovasc Interv, 86
(2007)
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trialLancet, 370
(2013)
Percutaneous left atrial appendage closure with the amplatzer and contraindications to anticoagulation therapy cardiac plug device in patients with nonvalvular atrial fibrillationJ Am Coll Cardiol, 62
(2014)
Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniquesEuroIntervention, 10
(2007)
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med, 146
(2011)
Comperative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) scoreJ Am Coll Cardiol, 57
(1996)
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillationAnn Thorac Surg, 61
(2009)
Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percuaneous Left Atrial Appendage Transcatheter Occlusion) StudyJACC Cardiovasc Interv, 2
(2011)
Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the bleeding academic research consortiumCirculation, 123
(2013)
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) TrialCirculation, 127
(2012)
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort studyEur Heart J, 33
(2013)
Transcatheter left atrial appendage closure for stroke prevention in atrial fibrillation with Amplatzer cardiac plug: the Belgian RegistryActa Cardiol, 68
(2010)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest, 138
(2014)
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trialJ Am Coll Cardiol, 64
(2009)
Dabigatran versus warfarin in patients with atrial fibrillationN Engl J Med, 361
(2015)
Idarucizumab for dabigatran reversalN Engl J Med, 373
(2010)
Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohortStroke, 41
(2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med, 365
(2013)
Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)J Am Coll Cardiol, 61
(1994)
Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulationClin Cardiol, 17
(Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2015;10(10). doi:10.4244/EIJY15M01_06.)
Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2015;10(10). doi:10.4244/EIJY15M01_06.Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2015;10(10). doi:10.4244/EIJY15M01_06., Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2015;10(10). doi:10.4244/EIJY15M01_06.
(2011)
Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) clinical trial and the Continued Access RegistryCirculation, 123
(Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2014. doi:10.4244/EIJY14M10_13.)
Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2014. doi:10.4244/EIJY14M10_13.Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2014. doi:10.4244/EIJY14M10_13., Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2014. doi:10.4244/EIJY14M10_13.
Cardiol Ther (2015) 4:167–177 DOI 10.1007/s40119-015-0053-z ORIGINAL RESEARCH Safety and Efficacy of Left Atrial Appendage Closure with the Amplatzer Cardiac Plug in Very High Stroke and Bleeding Risk Patients with Non-Valvular Atrial Fibrillation . . . . Julia Kebernik John Jose Mohamed Abdel-Wahab Bjo ¨ rn Sto ¨ cker Volker Geist Gert Richardt To view enhanced content go to www.cardiologytherapy-open.com Received: September 29, 2015 / Published online: November 13, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com received dual antiplatelet therapy for 6 months. ABSTRACT A transesophageal echocardiography (TEE) was Introduction: Limited data exist on the scheduled at 6 months. outcomes after left atrial appendage closure Results: Procedural success was 100%. TM (LAAC) with the Amplatzer Cardiac Plug Procedural-related complications occurred in (ACP; St. Jude Medical, Minneapolis, MN, 7.3% (pericardial effusion, 4.2%; thromboembolic USA) in patients with atrial fibrillation (AF) events, 2.1%; device embolization, 1.0%). with very high stroke and bleeding risks, the Additional thromboembolic events occurred subset expected to benefit most from this in three patients during follow-up (92.7% procedure. The objective of this study was to follow-up). After 93.4 patient-years of report clinical outcomes after LAAC with the follow-up, the annual rates
Cardiology and Therapy – Springer Journals
Published: Nov 13, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.